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1University of Oxford, Nuffield Department of Medicine, and 2Department of Clinical Research, London School of Hygiene and Tropical Medicine, United Kingdom; 3Biomedical Research and 
Training Institute, Harare, Zimbabwe; and 4Department of Clinical Research, Liverpool School of Tropical Medicine, United Kingdom
Background. Older children and adolescents with perinatally acquired human immunodeficiency virus (PHIV) infection in 
Africa experience multiple comorbidities that are not typical of HIV-associated opportunistic infections, including growth impair-
ment and chronic lung disease. We examined associations between plasma cytomegalovirus (CMV) DNA and lung function and 
growth.
Methods. Plasma CMV DNA loads were measured children aged 6–16 years with PHIV (n = 402) and HIV-uninfected controls 
(n = 224). The HIV-infected children were either newly diagnosed or known HIV infected and stable on antiretroviral therapy (ART) 
for >6 months. CMV DNA loads were measured using quantitative polymerase chain reaction. CMV DNAemia was modeled as a 
time-varying outcome using longitudinal mixed-effects logistic regression.
Results. At enrollment, CMV DNAemia ≥1000 copies/mL (defined as “clinically significant”) was detected in 5.8% of uninfected 
children, 14.7% of HIV-infected participants stable on ART, and 22.6% of HIV-infected ART-naive children (χ2 = 23.8, P < .001). The 
prevalence of CMV DNAemia ≥1000 copies/mL was associated with CD4 counts <350 cells/µL. Among HIV-infected ART-naive 
children, the presence of CMV DNAemia of ≥1000 copies/mL was independently associated with reduced lung function (adjusted 
odds ratio [aOR] = 3.23; 95% confidence interval [CI], 1.23–8.46; P = .017). Among ART-treated children, stunting was associated 
with CMV DNAemia of ≥1000 copies/mL (aOR = 2.79; 95% CI, 0.97–8.02; P = .057).
Conclusions. Clinically significant levels of CMV DNAemia were common in older children with PHIV, even those on ART, 
suggesting a role for inadequately controlled CMV infection in the pathogenesis of PHIV comorbidities in Africa.
Keywords. CMV; HIV; adolescent; chronic lung disease; stunting.
Before the widespread availability of antiretroviral therapy 
(ART), pediatric human immunodeficiency virus (HIV) in 
Africa was characterized by rapid disease progression, with 
<50% of children with perinatally acquired HIV infection 
(PHIV) surviving beyond 2 years [1]. At that time, the survival 
of HIV-infected children into adolescence seemed unlikely. 
However, it is now thought that one third of children with 
PHIV progress more slowly and can survive into their teens, 
even without ART [2]. The ART scale-up for PHIV in Africa 
has led to dramatic falls in mortality, leading to increasing 
numbers of ART-treated children reaching adolescence [3]. 
Long-term survival with PHIV, even for those on ART, is asso-
ciated with significant health problems that are not typical of 
HIV-associated opportunistic infections or AIDS-defining ill-
nesses [4]. Reports from sub-Saharan Africa have described sig-
nificant morbidity in older children with PHIV [4], including 
chronic lung disease (CLD), cardiac abnormalities [5], growth 
retardation, pubertal delay, and neurocognitive disorders. Many 
of these PHIV comorbidities have not previously been reported 
outside Africa, and their pathogenesis is poorly understood.
The most serious comorbidity described in older children 
with PHIV is CLD, reported in more than 30% of HIV-infected 
children aged >10  years in HIV care but frequently misdiag-
nosed and treated as pulmonary tuberculosis [6]. The severity 
of CLD was only recently recognized, and little is known about 
its etiology [6, 7]. Lung function and radiological abnormalities 
in older children with PHIV show no associations with either 
treatment status or ART duration, suggesting that once estab-
lished, this form of CLD does not respond to ART. Indeed, a 
recent study showed that 25% of older children with PHIV on 
ART (median treatment duration, 4.7 years; viral suppression 
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below detection in 79%) reported symptoms of CLD, predomi-
nantly cough and dyspnea [8].
We hypothesized that cytomegalovirus (CMV) might con-
tribute to the poor health of older children with PHIV, in view 
of the distinct epidemiology of CMV infection in sub-Saharan 
Africa. Most African infants acquire CMV infection in the first 
year of life, in contrast to developed countries where CMV infec-
tion occurs significantly later (mean age of 28.6 years in 1 large 
US study [9]). In the Gambia, 85% of infants acquired CMV 
infection by 1  year of age, increasing to 100% by 18  months 
[10]. HIV-uninfected infants generate potent cellular responses 
to CMV that are associated with viral control, although urinary 
CMV excretion may continue intermittently to age 5 years [11]. 
It is therefore highly likely that most African children with 
PHIV will acquire CMV coinfection in infancy.
CMV coinfection in ART-untreated infants with PHIV can 
lead to rapid disease progression [12, 13] and often infects the 
lungs, causing pneumonitis [14]. No studies have examined the 
long-term impact of infant CMV pneumonitis on subsequent 
lung function. However, it is plausible that repeated episodes of 
CMV pneumonitis or inflammation driven by subclinical CMV 
replication in HIV-infected children could lead to CLD.
We hypothesized that ART-untreated infants with PHIV who 
acquire CMV coinfection in early life fail to establish adequate 
immune control of CMV, leading to episodes of CMV reacti-
vation and/or persistent CMV replication that may increase 
immune activation and drive some of the comorbidities 
described in adolescent survivors of PHIV.
METHODS
Study Setting and Participants
We studied 626 participants within 2 prospective cohort stud-
ies investigating the natural history of comorbidities that affect 
children with PHIV, including lung function and growth. The 
ZENITH cohort recruited children aged 6–16 years who were 
newly diagnosed with HIV following provider-initiated HIV 
testing in primary healthcare clinics in Harare, Zimbabwe 
[15]. The INHALE cohort recruited children in the same 
age group who had been taking ART for >6 months from an 
HIV clinic at Harare Children’s Hospital, which served the 
same catchment population as the primary healthcare clin-
ics. Inclusion/exclusion criteria are described elsewhere [16, 
17]. PHIV diagnosis was made using criteria previously estab-
lished in Zimbabwe [4].
Spirometry was performed at baseline using EasyOne World 
spirometers (ndd Medical Technologies, Zurich, Switzerland) 
according to American Thoracic Society standard procedures 
[7]. The highest forced expiratory volume in the first second of 
expiration (FEV1) and forced vital capacity (FVC) measure-
ments, that is, the volume of air exhaled with maximum effort 
after a full inspiration, were used, with other indices recorded 
from the best trace (largest total of FEV1 and FVC). Using the 
Global Lung Function Initiative 2012 reference ranges (account-
ing for height, sex, age, and ethnicity), lung function was con-
sidered abnormal if either FVC or FEV1:FVC ratio z scores were 
less than −1.64 (below the 10th centile). Height was recorded at 
baseline for all participants, and HIV-infected participants were 
followed for 18 months, with clinical and laboratory examina-
tions every 3 months. Blood samples were collected and plasma 
was separated on the same day at the Biomedical Research and 
Training Institute (BRTI) in Harare, then stored at −80°C until 
required.
Children who tested HIV negative in the same age group 
as cohort participants joined the study as population controls 
and provided a single blood sample without further follow-up. 
Recruitment started in January 2013, and follow-up lasted until 
April 2015 (Figure 1).
Extraction of CMV DNA From Plasma
Total viral nucleic acids were extracted at the BRTI laborato-
ries in Harare from 200 µL plasma using the QIAamp MinElute 
Virus Spin Kit (Qiagen, Hilden, Germany). Then, 60 µL of total 
viral nucleic acids including CMV DNA were eluted and imme-
diately stored at −80°C for subsequent testing.
CMV Detection and Quantification
CMV DNAemia detection and quantification was performed by 
quantitative polymerase chain reaction (PCR) using the RealStar 
CMV PCR kit v1.0 (Altona Diagnostics, Hamburg, Germany). 
CMV DNA was quantified with the QuantStudio 3 Real-Time 
PCR System (Applied Biosystems, CA) (see Supplementary 
Methods for details).
Statistical Analyses
“Clinically relevant” CMV viral load (VL) was defined as 
plasma CMV VL ≥1000 copies/mL. Stunting was defined as 
a height-for-age more than 2 standard deviations below the 
mean, using World Health Organization reference standards. χ2 
tests were used for univariate analysis. For multivariate analysis 
of time-varying outcomes, we used longitudinal mixed-meth-
ods logistic regression. ART-naive participants and those sta-
ble on ART were modeled separately. Data were analyzed using 
Stata v14.1 (StataCorp, College Station, TX). As a sensitivity 
analysis, we also examined associations of risk factors with 
prevalence of any detectable CMV DNA (see Supplementary 
Methods for details).
Ethical Considerations
Informed consent (parent or guardian) and assent (partic-
ipant) were obtained from all participants prior to enroll-
ment. The Medical Research Council of Zimbabwe, the BRTI 
Institutional Review Board, and the Ethics Committees of 
Harare City Health Department, Harare Central Hospital, 
and the London School of Hygiene and Tropical Medicine 
approved the study.
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RESULTS
Baseline Characteristics of Study Participants
A total of 626 children and adolescents age 6–16  years were 
included. When the first sample was taken, 177 were HIV 
infected and ART naive, 225 were HIV infected on ART for 
>6  months, and 224 were uninfected controls (Figure  1). 
Baseline characteristics are provided in Table  1. During fol-
low-up, 37 of the 177 originally ART-naive participants initi-
ated ART and had a sample taken at least 6 months after starting 
therapy (Figure 1). Their pre-ART samples were included in the 
ART-naive analysis, and post-ART samples were included in 
the analysis of ART-experienced participants. There were 889 
observations: 626 at baseline, 33 at 6 months, 37 at 12 months, 
159 at 18  months, and 34 at 24  months. The median age at 
recruitment was similar between groups (11  years), and 50% 
were female. Stunting was more prevalent among HIV-positive 
children than their uninfected counterparts (32.5% vs 9.6%). 
Stunting was also associated with age; prevalence was 13.0% for 
children aged 6–9 years, 23.3% for children aged 10–12 years, 
and 39.6% for children aged >13  years (χ2  =  37.5, P  <  .001). 
Abnormal lung function (defined as described above) was 
common, ranging from 15.5% in the uninfected group to 
24.1% in the group stable on ART and 29.4% in the ART-naive 
HIV-positive group.
CMV DNAemia was detected in 8.9% of uninfected chil-
dren, 24.0% of HIV-positive participants established on ART, 
and 38.4% of the HIV-positive ART-naive children. At baseline, 
the prevalence of clinically relevant CMV DNAemia (CMV VL 
≥1000 copies/mL) in the uninfected, HIV-positive on ART, and 
HIV-positive ART-naive groups was 5.8%, 14.7%, and 22.6%, 
respectively (χ2 = 23.8, P < .001; Table 1).
Association Between CD4 Count and CMV Viral Load
Of the 55 HIV-positive participants with clinically significant 
CMV DNAemia at enrollment, 52% were on ART for >2 years 
before joining the cohort. The proportion of children with 
clinically relevant CMV viremia was inversely associated with 
CD4 count at recruitment in the ART-stable group (Table 1). 
In a multivariate analysis controlling for repeated measures 
and adjusting for ART status, age, and sex, CD4 count <350 
cells/µL was associated with more than twice the odds of CMV 
VL >1000 copies/mL (Table 2). After adjusting for CD4 count, 
age, and sex, no longer being on ART showed significant pro-
tection against high CMV DNAemia; however, each addi-
tional year on ART was associated with 0.84 the odds of CMV 
VL ≥1000 copies among ART-treated participants (Table  3), 
even after adjusting for CD4 count. HIV RNA <1000 copies/
mL was not associated with CMV DNAemia among partici-
pants on ART (Table 3).
Stunting Is Associated With HIV and High CMV DNAemia
At baseline, 29.2% of HIV-infected ART-naive participants and 
34.3% of those on ART were stunted compared to 9.6% of HIV-
uninfected participants (Table  1). In ART-naive HIV-infected 
participants, the prevalence of CMV VL ≥1000 copies/mL was 
higher among stunted than nonstunted participants (40.8% vs 
14.3%, χ2 = 14.2, P < .001). In participants who were on ART or 
Figure 1. Flow chart of study participants. Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; INHALE, INvestigation of Heart And Lung disEase 
among older children in Harare; ZENITH, Zimbabwe study for ENhancing Testing and Improving Treatment of HIV in children. 
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HIV negative, the prevalence of CMV VL ≥1000 copies/mL was 
similar among stunted and nonstunted participants (Table 1).
Association of Lung Function With High CMV DNAemia
A total of 89 participants did not have spirometry measure-
ments of sufficient quality to allow lung function assessment. 
Both reduced FVC and spirometric features of obstruction 
were more common in HIV-infected than HIV-uninfected par-
ticipants, particularly obstruction, which was more prevalent 
among ART-naive participants (Table  1). At baseline, 29.1% 
of stunted children compared to 20.8% of nonstunted children 
had abnormal lung function (reduced FVC or obstruction) in 
all 3 groups combined (χ2 = 3.85, P = .05). Only in HIV-positive 
ART-naive participants was high CMV DNAemia prevalence 
greater among those with abnormal lung function (Table 1).
In a longitudinal analysis of ART-naive HIV-positive partic-
ipants, reduced FVC was independently associated with high 
CMV DNAemia after adjusting for gender, age, CD4 count, and 
individual-level clustering (Table  4). Stunting and obstructive 
spirometry were not associated with CMV VL. Similar analysis 
Table 2. Multivariate Model of Risk Factors for High Cytomegalovirus DNAemia in All Human Immunodeficiency Virus–positive Participants
Characteristic Category
Univariatea Multivariatea
OR (95% CI) P Value OR (95% CI) P Value
CD4 count (cells/µL) ≥350 1 … 1 …
<350 2.70 (1.32, 5.51) .006 2.64 (1.25, 5.59) .011
Gender Male 1 … 1 …
Female 0.85 (0.48, 1.49) .563 0.86 (0.46, 1.58) .618
Age (years; ref: 6 years) 0.96 (0.87, 1.06) .425 0.94 (0.83, 1.06) .313
ART status Naive 1 1 …
>6 months on ART 0.43 (0.24, 0.78) .005 0.61 (0.32, 1.16) .132
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio; ref, reference group, controlling for clustering by individual.
aA total of 402 participants contributing 665 records were used in univariate analysis, while 367 participants contributing 591 records were used in model 1.
Table 1. Baseline Characteristics of the Study Population and Prevalence of High Cytomegalovirus DNAemia
Characteristic Category
HIV Negativea HIV Positive on ARTa HIV Positive ART-Naivea
N (%)
CMV ≥1000
n/N (%) N (%)
CMV ≥1000
n/N (%) N (%)
CMV ≥1000
n/N (%)
Gender Male 108 (48.2) 5/108 (4.6) 114 (50.7) 17/114 (14.9) 90 (50.9) 19/90 (21.1)
Female 116 (51.8) 8/116 (6.9) 111 (49.3) 16/111 (14.4) 87 (49.1) 21/87 (24.1)
Age (years) 6–9 83 (37.1) 9/83 (10.8) 72 (32.0) 10/72 (13.9) 73 (41.2) 16/73 (23.3)
10–12 72 (32.1) 3/72 (4.2) 92 (40.9) 13/92 (14.1) 58 (32.8) 11/58 (19.0)
13–16 69 (30.8) 1/69 (1.5) 61 (27.1) 10/61 (16.4) 46 (26.0) 12/46 (26.1)
Height for ageb Stunted 21 (9.6) 1/21 (4.8) 77 (34.3) 12/77 (15.6) 49 (29.2) 20/49 (40.8)
Not stunted 198 (90.4) 12/198 (6.1) 147 (65.7) 21/147 (14.3) 119 (70.8) 17/119 (14.3)
Lung functionc Normal 158 (84.5) 10/158 (6.3) 148 (75.9) 23/148 (15.5) 108 (63.3) 22/108 (20.4)
Reduced forced vital capacity 22 (11.8) 1/22 (4.6) 38 (19.5) 4/38 (10.5) 29 (17.5) 9/29 (31.0)
Obstruction 7 (3.8) 0 (0.0) 9 (4.6) 1/9 (11.1) 16 (9.6) 5/16 (31.3)
CD4 count (cells/µL)d ≤349 … 23 (10.5) 6/23 (26.1) 48 (35.1) 11/48 (22.9)
350–499 … 39 (17.7) 5/39 (12.8) 22 (14.9) 3/22 (13.6)
≥500 … 158 (71.8) 20/158 (12.7) 67 (50.0) 13/67 (19.4)
CMV VL (copies/mL of plasma) Undetectable 204 (91.1) 171 (76.0) 109 (61.6)
1–999 7 (3.1) 21 (9.3) 28 (15.8)
1000–9999 13 (5.8) 27 (12.0) 34 (19.2)
≥10 000 0 (0.0) 6 (2.7) 6 (3.4)
HIV RNA (copies/mL of plasma) ≤999 … … 180 (84.1) 25/178 (14.0) … …
1000–9999 … … 6 (2.8) 0/6 (0.0) … …
≥10 000 … … 28 (13.1) 5/28 (17.9) … …
Abbreviations: ART, antiretroviral therapy; CMV, cytomegalovirus; HIV, human immunodeficiency virus; VL, viral load.
aOf the total number of participants, 224 were HIV negative, 225 HIV positive on ART, and 177 HIV positive/ART-naive.
bData on stunting were missing for 5 HIV-uninfected and 9 HIV-positive/ART-naive participants.
cThe numbers of children with successful and interpretable lung function test data (spirometry test) at recruitment were 187 (HIV negative), 192 (HIV positive on ART), and 153 (HIV positive/
ART-naive).
dCD4 count was not measured for the uninfected group, and the data were available for 357/402 HIV-positive participants.
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in HIV-positive participants on ART revealed that CD4 count 
<350 cells/µL and stunting (albeit weakly) were independently 
associated with high CMV DNAemia, while longer time on 
ART was associated with lower odds of high CMV DNAemia 
(Table  3). Abnormal lung function was not included in the 
model as there was no evidence it was associated with outcomes 
of participants on ART in univariate analysis.
When the outcome was defined as any detectable CMV, lung 
function and stunting were not associated with CMV DNAemia in 
multivariate analysis among ART-naive or ART-treated participants. 
Being on ART for at least 6 months was associated with lower odds 
of detectable CMV DNA in plasma (adjusted odds ratio, 0.54; 95% 
confidence interval, 0.31–0.93; P = .026; Supplementary Table 1).
Analysis of longitudinal samples taken 18 months apart from 
a subset of 159 children and adolescents with PHIV showed that 
15.7% (20/127) of participants with undetectable CMV DNA at 
baseline had detectable levels of CMV DNA in their 18 month 
samples and vice versa (Table 5).
DISCUSSION
We investigated the hypothesis that poorly controlled CMV 
coinfection, acquired in infancy in most African children, could 
Table 3. Multivariate Model of Risk Factors for High Cytomegalovirus DNAemia in Participants on Antiretroviral Therapy
Characteristic Category
Univariatea Multivariate: A Priori Onlya
Multivariate: A Priori or  
Associated With Outcomea
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Years since antiretroviral therapy ini-
tiation (ref: 0)
… 0.81 (0.69, 0.95) .010 0.83 (0.69, 0.99) .035 0.84 (0.70, 1.00) .050
CD4 count (cells/µL) ≥350 1 … 1 … 1 …
<350 3.92 (1.20, 12.77) .023 3.75 (1.09, 12.94) .036 4.39 (1.20, 16.04) .025
Gender Male 1 … 1 … 1 …
Female 0.64 (0.27, 1.51) .311 0.69 (0.27, 1.74) .430 0.80 (0.31, 2.10) .655
Age (y; ref: 6 y) … 0.99 (0.85, 1.15) .884 0.94 (0.79, 1.12) .469 0.91 (0.75, 1.09) .305
Height for age Normal 1 … … … 1 …
Stunted 3.01 (1.17, 7.77) .022 … … 2.79 (0.97, 8.02) .057
Lung function Normal 1
Reduced forced 
vital capacity
1.22 (0.39, 3.80) .727 … …
Obstructed 0.41 (0.03, 6.52) .527 … …
HIV RNA (337 records) ≥1000 1.01 (0.25, 4.03) .988 … …
<1000 1 … … …
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group, controlling for clustering by individual.
aA total of 262 participants contributing 434 records were used in univariate analysis; 256 participants contributing 411 records were used in model 1, and 251 participants contributing 405 
records were used in model 2. 
Table 4. Multivariate Model of Risk Factors for High Cytomegalovirus DNAemia in Antiretroviral Therapy–naive Human Immunodeficiency Virus–positive 
Participants
Characteristic Category
Univariatea Multivariate: A priori Onlya
Multivariate: A priori or  
Associated With Outcomea
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
CD4 count (cells/µL) ≥350 1 … 1 … 1 …
<350 1.47 (0.67, 3.24) .340 1.55 (0.68, 3.54) .297 1.05 (0.40, 2.78) .916
Gender Male 1 ... 1 ... 1 ...
Female 1.10 (0.56, 2.16) .793 1.15 (0.54, 2.45) .714 1.17 (0.49, 2.79) .723
Age (y; ref: 6 y) 0.97 (0.85, 1.10) .619 0.95 (0.81, 1.11) .514 0.94 (0.78, 1.14) .552
Height for age Normal 1 ... ... ... 1 ...
Stunted 4.23 (1.47, 12.16) .008 ... ... 2.02 (0.78, 5.27) .150
Lung function Normal 1 ... ... ... 1 ...
Reduced forced vital 
capacity
2.11 (0.89, 4.98) .088 ... ... 3.23 (1.23, 8.46) .017
Obstructed 1.47 (0.49, 4.41) .485 ... … 2.04 (0.48, 8.70) .336
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group, controlling for clustering by individual.
aA total of 177 participants contributing 231 records were used in univariate analysis, 143 participants contributing 180 records were used in model 1, and 138 participants contributing 169 
records were used in model 2.
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contribute to the comorbidities of older children and adoles-
cents with PHIV. We found a surprisingly high prevalence of 
CMV DNAemia in older children with PHIV, both those with 
a new HIV diagnosis who had not yet started ART and those 
regarded as stable on ART. CMV DNAemia >1000 copies/mL 
was significantly associated with 2 major PHIV comorbidities, 
stunting and reduced lung function.
CLD in older children with PHIV was first described in 
Zimbabwe and subsequently reported in Malawi [18] and 
Kenya [19]. Radiological features strongly suggest obliterative 
bronchiolitis (OB) as the main cause [7], in which inflamma-
tion of the small airway leads ultimately to partial or complete 
bronchiolar obstruction. In high-income settings, OB is most 
often associated with allograft immune responses following 
lung or hematopoietic stem cell transplantation [20]; subclini-
cal CMV infection has been linked with increased OB risk after 
lung transplantation [21]. Reports from the southern hemi-
sphere describe OB following severe respiratory infections in 
early childhood [22]. As the epidemiology of CMV infection is 
distinct between sub-Saharan Africa and developed countries, 
we postulated that early CMV infection could contribute to the 
striking comorbidities associated with PHIV in Africa [4].
The trajectory of CMV viremia and shedding after primary 
infection remains poorly understood. Children infected in 
infancy were reported to secrete CMV in urine until the age of 
5  years. However, a large cross-sectional survey in the United 
States showed that 9.7% of the CMV immunoglobulin (Ig) 
G-positive population aged 6–49 years were excreting CMV in 
urine [23]. Urinary CMV shedding was most common in the 
youngest participants (26.6% in children aged 6–11 years) but 
was also detected in adolescents (6.5% in those aged 12–19 years). 
Even less is known about the dynamics of CMV viremia. In one 
study of hospitalized children aged 3 weeks to 2 years in Lusaka, 
Zambia, CMV was detected in the blood of 41% and was associ-
ated with being HIV infected, underweight, and presenting with 
meningitis [24]. Two age peaks of CMV DNAemia were noted, 
particularly in HIV-infected children, one in the first year of life 
and a second around 18–20 months of age. This was interpreted 
as either CMV reactivation or potentially reinfection. CMV 
DNAemia is rare in healthy adults (CMV DNA was found in 
only 2/416 CMV IgG-positive blood donors in the United States 
[25]). However, CMV is frequently reactivated during pregnancy 
and lactation, particularly in HIV-infected women, leading to 
viral shedding in the cervix and breastmilk. In HIV-uninfected 
pregnant women, CMV DNA is rarely detected in blood but may 
be found in the cervix of 37% CMV IgG-positive women, partic-
ularly during the third trimester [26]. In HIV-infected Kenyan 
women taking ART to prevent mother-to-child HIV transmis-
sion, CMV was detected in the cervix and breastmilk of 66% and 
99% of participants, respectively, although CMV was only found 
in blood in 4.8% [27]. Increased CMV shedding in the cervix 
and breastmilk of HIV-infected women who are close to delivery 
increases the risk of both congenital and early CMV infection 
in their infants [27]. Although ART used to prevent mother-to-
child HIV transmission during pregnancy reduces the risk of 
congenital CMV infection [13], the reduction in early postnatal 
CMV transmission is only modest [28].
The burden of severe opportunistic CMV infection, causing 
common AIDS-defining conditions such as retinitis, colitis, 
and esophagitis, has decreased substantially with the availabil-
ity of ART. Nevertheless, studies of HIV-infected adults in the 
developed world have shown that subclinical CMV DNAemia 
(ie, CMV DNA detected in blood without clinical evidence of 
CMV disease) strongly predicts accelerated disease progression 
and early mortality, even in patients taking ART [29]. Increased 
levels of CMV antibodies or T-cell responses (potentially driven 
by CMV reactivation) are associated with both elevated immune 
activation [30] and the non-AIDS–defining comorbidities 
increasingly seen in the aging population of HIV-infected peo-
ple on long-term ART [31]. There are fewer studies in Africa, 
but one study of South African miners with relatively early HIV 
disease in the pre-ART era reported that CMV DNAemia (5.2% 
prevalence) was associated with a 3-fold increase in mortality 
[32]. In that study, higher CMV VLs (≥1000 copies/mL, our cut-
off for clinically significant CMV DNAemia) were linked with 
significantly higher mortality (adjusted hazard ratio, 3.65) [32].
A recent metaanalysis showed that early CMV coinfection led 
to accelerated disease progression in ART-untreated infants with 
PHIV [13]. However, there is little information about the impact 
of CMV coinfection on HIV-infected children taking cART, 
particularly in Africa. Maternal CMV DNAemia close to deliv-
ery was associated with increased mortality of both mother and 
baby in a Kenyan cohort with limited ART access [33]. HIV and 
CMV plasma VLs closely correlated in the HIV-CMV–coinfected 
infants in this study, thought to reflect CMV-driven immune 
activation that fueled HIV replication in activated T cells [34, 35]. 
As CMV replication (like HIV) is enhanced by inflammation, the 
virus has developed strategies to promote immune activation, 
including direct upregulation of proinflammatory cytokines such 
as interleukin (IL)-1β, tumor necrosis factor-α, and IL-6 [36]. 
The association of CMV infection with inflammation is more 
Table  5. Frequency of Cytomegalovirus DNAemia in a Subset of 
Longitudinal Samples From the Human Immunodeficiency Virus–positive 
Group
CMV DNA at 18 Months
Detected Not Detected Totala
CMV DNA at baseline Detected 11 21 32
Not detected 20 107 127
Total 31 128 159
Abbreviation: CMV, cytomegalovirus.
aNumber of participants with 2 samples taken 18 months apart. The presence and quantity 
of CMV DNA was measured in both samples (baseline and follow-up) at the same time in 
a single plate to minimize intra- and interassay variability.
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marked in HIV-infected patients [37]. CMV was recently shown 
to be replicating in the gut mucosa of HIV-infected adults (even 
those on ART); this was associated with disruption of mucosal 
integrity, translocation of gut microbial products, and increased 
inflammation [38]. A trial of the anti-CMV drug valganciclovir 
in HIV-infected adults with incomplete immune reconstitution 
on ART showed that CMV suppression was significantly associ-
ated with reduced T-cell activation [39].
Our study has strengths and some limitations. We studied a 
large well-characterized group of HIV-infected older children 
with PHIV, both treated and untreated, as well as age- and sex-
matched controls from the same population. An important 
limitation is the lack of information about HIV RNAs in the 
ART-naive participants at enrollment (not routinely measured 
at the time in Zimbabwe.) The INHALE participants described 
as stable on ART may have elevated HIV RNAs because of poor 
adherence, which is characteristic of HIV-infected adolescents 
[40]. However, HIV RNA data, available from 337 of 434 sam-
ples from participants on ART, showed no association between 
HIV RNA and CMV DNAemia in univariate analysis. Last, our 
data do not allow us to determine the direction of associations, 
so we cannot conclude that CMV is a cause of stunting or CLD. 
An alternative interpretation would be that all 3 are independent 
but causally unrelated markers of progressive PHIV disease.
Additional studies are needed to establish the potential role 
of CMV reactivation in the pathogenesis of the serious com-
plications of PHIV in Africa and to determine whether or not 
specific antiviral drugs such as valganciclovir might be useful in 
these conditions.
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